Please select the option that best describes you:
What is your preferred BTK inhibitor for patients with relapsed/refractory mantle cell lymphoma?
How do you generally think about sequencing treatment among available options?
Would your choice be affected by a patient's eligibility for transplant or CAR-T therapy?
Answer from: Medical Oncologist at Academic Institution
The majority of patients with relapsed/refractory MCL will respond to single agent BTKi therapy and this is my preferred treatment in patients at first relapse when a clinical trial is not available, and they have not been exposed to a BTKi (for example, on a frontline clinical trial). I often used ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
That is a tough one. I have largely moved away from ibrutinib given the side effect profile. Though, I should add that if I have a patient on chronic therapy tolerating without significant side effects, I do not change therapy. With regards to second generation BTKi's, I have been giving more zanubr...
Answer from: Medical Oncologist at Community Practice
Zanbrutinib